1519 related articles for article (PubMed ID: 23553340)
1. Development and regulation of biosimilars: current status and future challenges.
Tsiftsoglou AS; Ruiz S; Schneider CK
BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
[TBL] [Abstract][Full Text] [Related]
2. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
Ahmed I; Kaspar B; Sharma U
Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
[TBL] [Abstract][Full Text] [Related]
3. Demonstration of biosimilarity, extrapolation of indications and other challenges related to biosimilars in Europe.
Tsiftsoglou AS; Trouvin JH; Calvo G; Ruiz S
BioDrugs; 2014 Dec; 28(6):479-86. PubMed ID: 25391420
[TBL] [Abstract][Full Text] [Related]
4. [Biosimilars, the journey has begun].
Martos-Rosa A; Martínez-de la Plata JE; Morales-Molina JA; Fayet-Pérez A; Acosta-Robles PJ
Farm Hosp; 2015 Mar; 39(2):114-7. PubMed ID: 25817091
[TBL] [Abstract][Full Text] [Related]
5. Upcoming Drifts in Bio-similars.
Aggarwal G; Nagpal M; Sharma A; Puri V; Dhingra GA
Curr Rev Clin Exp Pharmacol; 2021; 16(1):39-51. PubMed ID: 32379595
[TBL] [Abstract][Full Text] [Related]
6. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
Jahnz-Rozyk K; Wiesik-Szewczyk E;
Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars: Rationale and current regulatory landscape.
Olech E
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
[TBL] [Abstract][Full Text] [Related]
9. Biosimilar regulation in the EU.
Kurki P; Ekman N
Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076
[TBL] [Abstract][Full Text] [Related]
10. The US approach to biosimilars: the long-awaited FDA approval pathway.
Calvo B; Zuñiga L
BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
[TBL] [Abstract][Full Text] [Related]
11. From bioequivalence to biosimilars: How much do regulators dare?
Weise M
Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000
[TBL] [Abstract][Full Text] [Related]
12. Review on the worldwide regulatory framework for biosimilars focusing on the Mexican case as an emerging market in Latin America.
Ibarra-Cabrera R; Mena-Pérez SC; Bondani-Guasti A; García-Arrazola R
Biotechnol Adv; 2013 Dec; 31(8):1333-43. PubMed ID: 23714280
[TBL] [Abstract][Full Text] [Related]
13. Development of biosimilars.
Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
[TBL] [Abstract][Full Text] [Related]
14. Clinical data and regulatory issues of biosimilar products.
Stevenson JG
Am J Manag Care; 2015 Dec; 21(16 Suppl):s320-30. PubMed ID: 26788808
[TBL] [Abstract][Full Text] [Related]
15. Frontiers in nonclinical drug development: biosimilars.
Ryan AM
Vet Pathol; 2015 Mar; 52(2):419-26. PubMed ID: 25161206
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars and the European experience: implications for the United States.
Megerlin F; Lopert R; Taymor K; Trouvin JH
Health Aff (Millwood); 2013 Oct; 32(10):1803-10. PubMed ID: 24101072
[TBL] [Abstract][Full Text] [Related]
17. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
18. Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges.
Chapman K; Adjei A; Baldrick P; da Silva A; De Smet K; DiCicco R; Hong SS; Jones D; Leach MW; McBlane J; Ragan I; Reddy P; Stewart DI; Suitters A; Sims J
MAbs; 2016; 8(3):427-35. PubMed ID: 26854177
[TBL] [Abstract][Full Text] [Related]
19. Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use.
Cilia M; Ruiz S; Richardson P; Salmonson T; Serracino-Inglott A; Wirth F; Borg JJ
AAPS PharmSciTech; 2018 Feb; 19(2):489-511. PubMed ID: 29027130
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars: current status and future directions.
Roger SD
Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
